Transformational year for Galapagos
Strong balance sheet for continued growth Key 2019 events: Unique R&D agreement signed with collaboration partner Gilead Applications for approval of selective JAK1 inhibitor filgotinib in rheumatoid arthritis (RA) in the U.S., Europe and Japan by …